In the U.S., Actavis Specialty Brands focuses on delivering innovative products that address disease states in Urology and Women’s Health.
Leading marketed products included RAPAFLO®, Gelnique®, Trelstar®, Androderm®, Crinone® and Generess® Fe.In 2012, Actavis Specialty Brands launched Gelnique 3%TM.
We also invested approximately $146 million in Specialty Brands R&D.
These products are promoted by a sales team of approximately 430 representatives focused on strengthening our coverage of urologists and obstetricians and gynecologists. Approximately 54 members of our sales team focus on institutions and clinics.
US Product Database